Large molecule bioanalysis workflow solution
The accurate determination of pharmacokinetic properties of biologic molecules is one important part in the development process of biotherapeutic drugs. Currently, enzyme-linked immunoassays (ELISA) are the gold-standard to measure the concentration of therapeutic antibodies and protein biomarkers but they require lengthy development of custom antibodies and can be prone to severe matrix effects, resulting in inaccurate measurements.
As an attractive alternative, liquid chromatography (LC) in combination with quantitative mass spectrometry (MS) and sophisticated sample enrichment workflows is now available for the bioanalysis of therapeutic proteins. LC-MS workflows offer superior specificity and sensitivity and interferences from complex sample matrices are basically eliminated.
King’s College Hospital, London, presents applications of MSIA for solving challenging protein quantitation problems.
MSIA Workflow for Therapeutic Antibodies: Qualitative, Quantitative, and Functional Verification Data from HR/AM Detection of Intact, Reduced, and Peptide-level Forms of Adalimumab
The biopharmaceutical industry has adopted biologics as a major component of their drug portfolios and developing pipelines. At the forefront of this drug class are monoclonal antibodies (mAb), highly discriminative molecules that can be engineered for specific targets. The rapid adoption of this class of biologics is due to their high affinity for their targets, selective biological actions, predictability of common side effects, and standardization of manufacturing processes.
LC-MS/MS Method for the Determination of Raloxifene and its Glucuronide Metabolites from Human Plasma Using SPE Micro Elution
A simple, rapid, and sensitive method for the determination of raloxifene (RAL) and its two active metabolites, raloxifene-4-glucuronide (R4G) and raloxifene-6-glucuronide (R6G), in human plasma by liquid chromatographytandem mass spectrometry using raloxifene-d4 as an internal standard was developed and evaluated.